A detailed history of Jump Financial, LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 60,766 shares of ARCT stock, worth $955,849. This represents 0.03% of its overall portfolio holdings.

Number of Shares
60,766
Previous 15,848 283.43%
Holding current value
$955,849
Previous $385,000 266.23%
% of portfolio
0.03%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.08 - $25.38 $812,117 - $1.14 Million
44,918 Added 283.43%
60,766 $1.41 Million
Q2 2024

Aug 14, 2024

BUY
$24.35 - $44.39 $385,898 - $703,492
15,848 New
15,848 $385,000
Q2 2023

Oct 21, 2024

SELL
$23.94 - $32.36 $807,951 - $1.09 Million
-33,749 Reduced 80.85%
7,992 $229,000
Q2 2023

Aug 07, 2023

SELL
$23.94 - $32.36 $807,951 - $1.09 Million
-33,749 Reduced 80.85%
7,992 $229,000
Q1 2023

Oct 21, 2024

BUY
$14.72 - $23.97 $381,144 - $620,655
25,893 Added 163.38%
41,741 $1 Million
Q1 2023

May 03, 2023

BUY
$14.72 - $23.97 $312,991 - $509,674
21,263 Added 103.83%
41,741 $1 Million
Q4 2022

Feb 13, 2023

BUY
$14.14 - $23.06 $289,558 - $472,222
20,478 New
20,478 $347,000
Q2 2022

Aug 09, 2022

BUY
$12.26 - $31.17 $305,936 - $777,816
24,954 New
24,954 $393,000
Q1 2022

May 12, 2022

SELL
$17.64 - $39.57 $537,014 - $1.2 Million
-30,443 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$34.2 - $47.56 $1.04 Million - $1.45 Million
30,443 New
30,443 $1.13 Million
Q2 2021

Aug 13, 2021

SELL
$25.79 - $42.11 $912,966 - $1.49 Million
-35,400 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$38.75 - $86.92 $1.37 Million - $3.08 Million
35,400 New
35,400 $1.46 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $418M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.